Drug intelligence / Profile preview

ORMD-0601

Development stage: Unknown
Lead developer: Oramed Pharmaceuticals

Overview

ORMD-0601 is an investigational oral drug developed by Oramed Pharmaceuticals. It is part of Oramed’s pipeline of oral delivery therapies; however, the specific active ingredient, mechanism of action, and clinical data for ORMD-0601 are not publicly available from the sources reviewed. Oramed is known for pioneering oral peptide formulations, particularly oral insulin (ORMD-0801) and oral GLP-1 analogs (ORMD-0901), but there is no detailed description or indication of what molecule ORMD-0601 represents or for which condition it is being developed in accessible public documents[1][3].

Beyond the preview

Go deeper on ORMD-0601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORMD-0601.

Explore the full profile